1-9 of 9
Zonghai LI
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4845.
https://doi.org/10.1182/blood-2023-184373
Published: 2023
Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Daijing Yuan, Hongxia Zhao, Jun Xiao, Wei Wang, Huamao Wang, Zonghai LI
Journal: Blood
Blood (2022) 140 (Supplement 1): 4564–4565.
https://doi.org/10.1182/blood-2022-168610
Published: 2022
Journal Articles

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Zhen Cai, Zonghai Li, Huijuan Wang, Lingzhi Yan, Yin Wu, Xiaolan Shi, Wen Gao, Shuang Yan, Wei Wang, Xiaoyan Han, Gaofeng Zheng, Yanling Wen, Jun Xiao, Huamao Wang, Xiaole Tang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2821.
https://doi.org/10.1182/blood-2021-150124
Published: 2021
Journal Articles

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

Chengcheng Fu, Songfu Jiang, Jie Jin, Wenming Chen, Siguo Hao, Zhen Cai, Zonghai LI, Lingzhi Yan, Kang Yu, Min Yang, Huijuan Wang, Wenhao Zhang, Xiaoyan Han, Wei Wang, Hongxia Zhao
Journal: Blood
Blood (2021) 138 (Supplement 1): 1751.
https://doi.org/10.1182/blood-2021-151935
Published: 2021
Journal Articles

Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Siguo Hao, MD PhD, Jie Jin, MD PhD, Songfu Jiang, MD, Zonghai Li, MD PhD, Wenhao Zhang, MD PhD, Min Yang, MD PhD, Kang Yu, MD, Wei Wang, MDPhD, Linjun Chen, MD PhD, Haitao Meng, MD PhD, Mingxia He, MD, Jun Xiao, MD, Rong Tao, MD PhD, Xin Huang, MD PhD, Chongyun Xing, MD, Daijing Yuan, MD, Jianbo Wan, MD PhD, Shasha Wang, MD PhD, Lihui Dai, BS, Hong Ma, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140156
Published: 2020
Journal Articles

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Shaji K. Kumar, MD, Rachid C. Baz, MD, Robert Z. Orlowski, MDPhD, Larry D. Anderson, Jr., MD PhD, Hong Ma, MD, Alexandria Shrewsbury, MS, Katrina A. Croghan, M.S., Mrinalini Bilgi, MS, Ankit Kansagra, MD, Prashant Kapoor, MD, Zonghai Li, MD PhD, Jason Brayer, PhDMD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-139802
Published: 2020
Journal Articles

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD PhD, Chengcheng Fu, MD PhD, Zhen Cai, MD PhD, Zonghai Li, MD PhD, Huijuan Wang, MD PhD, Lingzhi Yan, MD PhD, Yin Wu, MD PhD, Xiaolan Shi, MD PhD, Wen Gao, MD, Shuang Yan, MD, Wei Wang, MDPhD, Xiaoyan Han, MD PhD, Gaofeng Zheng, MD PhD, Yanling Wen, MD, Jun Xiao, MD, Huamao Wang, PhD, Hong Ma, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140727
Published: 2020
Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Jin Jie, MD PhD, Siguo Hao, MD PhD, Songfu Jiang, MD, Zonghai Li, MD PhD, Min Yang, MD PhD, Wenhao Zhang, MD PhD, Kang Yu, MD, Jun Xiao, MD, Haitao Meng, MD PhD, Liyuan Ma, MD PhD, Mingxia He, MD, Wei WANG, MD PhD, Xin Huang, MD PhD, Linjun Chen, MD PhD, Chongyun Xing, MD, Daijing Yuan, MD, Shasha Wang, MD PhD, Rong Tao, MD PhD, Lihui Dai, BS, Hong Ma, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4435.
https://doi.org/10.1182/blood-2019-126104
Published: 2019
Journal Articles

Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma

Songfu Jiang, MD, Jie Jin, MD PhD, Siguo Hao, MD PhD, Min Yang, MD, Linjun Chen, MD, Huaying Ruan, MS, Jun Xiao, MD, Wei Wang, MD PhD, Zonghai Li, MD PhD, Kang Yu, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 960.
https://doi.org/10.1182/blood-2018-99-113220
Published: 2018